Podest I., Blannin A., Wallis G
According to NICE guidance (NG28), the continuation of GLP-1 receptor agonist therapy in type 2 diabetes should be assessed after six months, with treatment continued only if there is a reduction in HbA1c of at least 11 mmol/mol (1%) and, where applicable, a weight loss of at least 3% of initial body weight
Why injectable forms are considered safer Injectable semaglutide (Ozempic, Wegovy) and injectable tirzepatide (Mounjaro, Zepbound) are administered subcutaneously
Indeed, seven doctors who spoke with Fortune say the preponderance of medical trials so far show that generally, people who stop taking the drugs regain most of the weight theyve lost within about a year
Explore medical, genetic, and lifestyle causes and possible treatment options